This is great news, I was suggesting using magnetic nanoparticles to deliver the drug directly to the site but this makes even more sense.
http://www.medicalnewstoday.com/releases/247518.php
Researchers at the Wyss Institute for Biologically Inspired Engineering
at Harvard University have developed a novel biomimetic strategy that
delivers life-saving nanotherapeutics directly to obstructed blood
vessels, dissolving blood clots before they cause serious damage or even
death. This new approach enables thrombus dissolution while using only a
fraction of the drug dose normally required, thereby minimizing
bleeding side effects that currently limit widespread use of
clot-busting drugs.
The research findings, which were published online in the journal Science, have significant implications for treating major causes of death, such as heart attack, stroke, and pulmonary embolism, that are caused by acute vascular blockage by blood thrombi.
The inspiration for the targeted vascular nanotherapeutic approach came
from the way in which normal blood platelets rapidly adhere to the
lining of narrowed vessels, contributing to the development of
atherosclerotic plaques. When vessels narrow, high shear stresses
provide a physical cue for circulating platelets to stick to the vessel
wall selectively in these regions. The vascular nanotherapeutic is
similarly about the size of a platelet, but it is an aggregate of
biodegradable nanoparticles that have been coated with the clot-busting
drug, tissue plasminogen activator (tPA). Much like when a wet ball of
sand breaks up into individual grains when it is sheared between two
hands, the aggregates selectively dissociate and release tPA-coated
nanoparticles that bind to clots and degrade them when they sense high
shear stress in regions of vascular narrowing, such as caused by blood clot formation.
Disruption of normal blood flow to the heart, lung, and brain due to
thrombosis is one of the leading causes of death and long-term adult
disability in the developing world. Today, patients with pulmonary
embolism, strokes, heart attacks, and other types of acute thrombosis
leading to near-complete vascular occlusion, are most frequently treated
in an acute care hospital setting using systemic dosages of powerful
clot-dissolving drugs. Because these drugs can cause severe and often
fatal bleeding as they circulate freely throughout the body, the size of
the dosage given to any patient is limited because efficacy must be
balanced against risk.
The new shear-activated nanotherapeutic has the potential to overcome
these efficacy limitations. By targeting and concentrating drug at the
precise site of the blood vessel obstruction, the Wyss team has been
able to achieve improved survival in mice with occluded lung vessels
with less than 1/50th of the normal therapeutic dose, which should
translate into fewer side effects and greater safety. This raises the
possibility that, in the future, an emergency technician might be able
immediately administer this nanotherapeutic to anyone suspected of
having a life-threatening blood clot in a vital organ before the patient
even reached the hospital.
The inter-disciplinary and inter-institutional collaborative research
team, which was led by Wyss Founding Director Donald Ingber M.D., Ph.D.,
and Wyss Technology Development Fellow Netanel Korin, Ph.D., also
included Wyss postdoctoral Fellow Mathumai Kanapathipillai, Ph.D., as
well as Benjamin D. Matthews, Marilena Crescente, Alexander Brill,
Tadanori Mammoto, Kaustabh Ghosh, Samuel Jurek, Sidi A. Bencherif, Deen
Bhatta, Ahmet U. Coskun, Charles L. Feldman, and Denisa D. Wagner from
Brigham and Women's Hospital, Children's Hospital Boston, Harvard
Medical School, the Harvard School of Engineering and Applied Sciences,
and Northeastern University. Ingber is also the Judah Folkman Professor
of Vascular Biology at Harvard Medical School and Children's Hospital
Boston, and Professor of Bioengineering at Harvard's School of
Engineering and Applied Sciences.
Commenting on the work, Ingber noted that "the vascular nanotherapeutic
we developed that selectively becomes activated in regions of high shear
stress, much like living platelets do, is a wonderful example of how we
at the Wyss Institute take inspiration from biology, and how biomimetic
strategies can lead to new and unexpected solutions to age-old problems
that existing technologies can't address."
Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 28,972 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment